Author: Vivian Xie 22nd July 2026
Since it was passed into law in 2022, the Inflation Reduction Act (IRA) has forced the pharma industry to confront its most significant pricing policy transformation in decades. The first round of drugs to be released under this model were announced in summer 2023, and their negotiated prices came into effect at the start of 2026. Current pharmaceutical pricing strategies reflect their impact, with products seeing price reductions between 38% and 79% [1] compared to list prices.
The IRA’s impact also extends to all facets of drug price negotiations, from portfolio investment decisions and lifecycle management strategies to manufacturing cost optimisation initiatives. This marks a departure from the United States' historical approach to pharmaceutical pricing, which prohibited direct pricing negotiations with manufacturers under Medicare Part D and Part B programmes. The new framework gives the Centers for Medicare & Medicaid Services (CMS) authority to negotiate prices for select high-expenditure drugs which do not have generic or biosimilar competition, to a total of 30 Part D and Part B drugs [2] by 2029.
Pharmaceutical manufacturers face substantial penalties (namely, excise taxes at a starting rate of 65% of product sales, potentially escalating to 95%) if they refuse to come to the table for negotiations. This effectively forces them to participate, despite the act’s so-called voluntary status, and fundamentally alters the risk-return calculus for pharmaceutical investment, particularly for products targeting chronic conditions in elderly populations where Medicare represents the dominant payer.
For European pharmaceutical companies with substantial commercial exposure in the US, IRA pricing provisions pose new challenges, as impacted products are often those which generate disproportionate revenues in American markets compared with their domestic counterparts. With global pharma markets more interconnected than ever, any changes in pricing policy will have inevitable reverberations across the industry. Here’s what you need to understand in order to manage your portfolios successfully in this time of sector-wide change.


